Siti Muinah
The launch of the Healthy Taiwan Cultivation Plan in 2024 marked a pivotal shift in the nation’s healthcare trajectory, placing the resilience of the medical system and the sustainability of high-quality care at the forefront of the government’s agenda. Under the broader national vision of “Healthy Taiwan,” policymakers are now tasked with navigating a complex global landscape defined by rapid technological advancement and volatile supply chains. As medical technology continues to evolve at an unprecedented pace, the ability to integrate innovative medical devices into the clinical environment has become a critical barometer for Taiwan’s healthcare standards. Industry experts and regulatory committees are now calling for a comprehensive overhaul of the current framework, emphasizing that regulatory efficiency and predictable reimbursement pathways are no longer merely administrative goals but essential components of patient rights and national competitiveness.
The Strategic Context of the Healthy Taiwan Vision
The 2024 Healthy Taiwan Cultivation Plan is designed to address the dual challenges of an aging population and the increasing prevalence of chronic diseases. To achieve these goals, the government has recognized that the healthcare system must transition from a traditional service model to one that is driven by innovation. However, the introduction of cutting-edge technologies—ranging from AI-driven diagnostic tools to advanced surgical robotics—requires a regulatory environment that is both rigorous and agile.
Currently, Taiwan’s medical device market is characterized by a high reliance on international innovation, yet manufacturers often face significant hurdles in navigating the registration and reimbursement processes. The Committee on Medical Devices has noted that while the Taiwan Food and Drug Administration (TFDA) has made strides in modernization, the speed of global innovation is outpacing the current domestic review timelines. To maintain Taiwan’s status as a premier healthcare hub in Asia, the Committee suggests that the government must optimize the medical device registration framework, accelerate pre-market review periods, and enhance the transparency of the National Health Insurance (NHI) pricing mechanisms.
Chronology of Regulatory Evolution and Current Bottlenecks
The push for reform is not a new phenomenon but has gained significant momentum over the last two years. In 2023, the Taiwan White Paper highlighted the need for a more flexible manufacturing registration system. While the TFDA responded by allowing multiple production sites for certain kits and accessories, the policy has yet to be extended to single, high-value medical products. This limitation has created a significant bottleneck in supply chain management.
In the post-pandemic era, global manufacturing has shifted toward a decentralized model to mitigate risks associated with geopolitical instability, natural disasters, and material shortages. Many international medical technology firms now operate identical production lines across multiple continents. Under Taiwan’s current restrictive licensing, if a primary production site in Europe faces a disruption, a manufacturer cannot easily switch to an identical, approved site in the United States without undergoing a lengthy and redundant license amendment process. This lack of flexibility poses a direct threat to the continuity of medical services in Taiwan’s hospitals.
Suggestion 1: Modernizing the Licensing Framework for Global Supply Chains
To address these vulnerabilities, industry leaders recommend that Taiwan adopt a licensing model similar to that used for biologic drugs. This framework would allow a single medical device license to cover multiple production sites globally, provided that the manufacturer can demonstrate identical quality control systems and manufacturing processes across all locations.
This shift would align Taiwan with international best practices and ensure that healthcare institutions can pivot to alternative sources during global supply shocks. By permitting the simultaneous listing of multiple manufacturing sites, the TFDA would not only reduce the administrative burden on both the regulator and the industry but also safeguard patient access to essential life-saving devices.
Suggestion 2: Implementing International Regulatory Reliance and Recognition
One of the most transformative proposals involves the adoption of a "reliance-based" review system. This model, promoted by the World Health Organization (WHO), encourages regulatory authorities to give significant weight to the scientific assessments and decisions made by other trusted international bodies, such as the U.S. Food and Drug Administration (FDA), the European Union’s regulatory agencies, and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).
The Mechanics of Regulatory Reliance
Regulatory reliance does not mean a loss of sovereignty; rather, it is a strategic work-sharing approach. Taiwan could adopt a "one-way reliance model" where the TFDA references the data and approvals from mature markets to fast-track its own decisions. This would eliminate the need for duplicative clinical trials or redundant technical reviews that often delay a product’s entry into the Taiwan market by months or even years.
Phased Implementation and Transparency
The Committee proposes a four-pronged approach to implementing this system:
- Clear Guidelines: Issuing detailed manuals to help industry players understand the reliance criteria.
- Standardized Timelines: Establishing predictable windows for review to allow companies to plan their market entry effectively.
- Initial Alignment: Focusing first on approvals from the U.S., EU, and Japan before expanding the scope.
- Post-Market Surveillance: Shifting the focus from exhaustive pre-market barriers to robust monitoring once the device is in use, ensuring long-term safety without stifling initial access.
Furthermore, there is a strong call to phase out the requirement for a "Certificate of Free Sale" (CFS) for innovative technologies. Currently, a device must often be sold in its country of origin before it can be registered in Taiwan. This "follower" approach ensures that Taiwanese patients are often the last in the developed world to access new treatments. Removing this requirement for breakthrough technologies would allow Taiwan to become a launch market for global innovation.
Suggestion 3: Enhancing NHI Transparency and Tracking Systems
The National Health Insurance (NHI) system is the backbone of Taiwan’s healthcare, but its reimbursement process is often described as a "black box" by industry stakeholders. To improve this, the Committee recommends a significant upgrade to the National Health Insurance Administration (NHIA) online tracking platform.
Real-Time Case Management
By benchmarking the TFDA’s transparency standards, the NHIA could provide real-time updates on the status of reimbursement applications. This would include disclosing anticipated review steps and indicative timelines. Such transparency is vital for healthcare providers who need to manage their budgets and for patients who are waiting for new treatment options.
Updating Clinical Evidence
A recurring issue in the current system is the delay between a submission and the Health Technology Assessment (HTA). Often, by the time a device is reviewed, the clinical data provided two years prior is obsolete. The Committee suggests that the NHIA should disclose review schedules at least one year in advance, allowing applicants to submit the most current clinical evidence and real-world data just before the HTA begins. This would ensure that pricing decisions are based on the latest medical science rather than outdated reports.
Suggestion 4: Resolving the Self-Pay Regulatory Conflict
There is currently a disconnect between the statutory framework of the Medical Care Act and the operational practices of the NHIA regarding "self-pay" medical devices—those that are approved for use but not yet covered by insurance. While the NHIA claims these devices fall outside its jurisdiction, it still issues guidelines that hospitals feel compelled to follow to avoid audit risks.
This ambiguity has led to inconsistent management standards across different regions of Taiwan. The Committee recommends that the Department of Medical Affairs take a central role in consolidating these regulations. By issuing formal, unified guidance on how hospitals can charge for newly approved devices, the government can provide the legal certainty necessary for medical institutions to adopt new technologies quickly, even before they are fully reimbursed by the NHI.
Suggestion 5: Funding Innovation via Sandboxes and Acceleration Funds
Recognizing the constraints of the NHI’s global budget, the proposal introduces two innovative financial mechanisms: an NHI Sandbox and a Medical Innovation Acceleration Fund.
The NHI Sandbox for Imported Tech
Currently, sandbox discussions in Taiwan have largely focused on domestic startups. However, the Committee argues that the sandbox should be expanded to include imported innovative technologies. This would allow patients to access advanced devices while real-world evidence is collected within the Taiwanese population. This data could then be used to inform final pricing and reimbursement decisions, bridging the gap between regulatory approval and insurance coverage.
The Taiwan Medical Innovation Acceleration Fund
To further support the "Healthy Taiwan" vision, the establishment of a dedicated fund is proposed. This fund would provide annual resources specifically for the early clinical adoption of emerging technologies. By decoupling the initial cost of innovation from the primary NHI budget, Taiwan can foster a more dynamic healthcare ecosystem that rewards clinical value and improves patient outcomes without immediately straining the national insurance pool.
Broader Impact and Implications for the Future
The recommendations laid out by the Committee represent a holistic strategy to reinforce Taiwan’s healthcare infrastructure. By aligning domestic regulations with international standards, Taiwan can transform itself from a passive recipient of medical technology into a proactive leader in clinical innovation.
The implications of these reforms extend beyond the medical sector. A more efficient regulatory environment will attract increased foreign investment, as global medtech firms view Taiwan as a stable, predictable, and forward-thinking market. More importantly, these changes will directly benefit the Taiwanese people. Faster access to precision surgical tools, advanced implants, and digital health solutions will lead to shorter recovery times, better chronic disease management, and a higher overall quality of life.
As the government moves forward with the Healthy Taiwan Cultivation Plan, the integration of these five suggestions will be crucial. The path to a resilient healthcare system lies in the balance between rigorous safety oversight and the agile adoption of the technologies that define 21st-century medicine. Through collaboration between the TFDA, NHIA, and the private sector, Taiwan has the opportunity to set a global benchmark for healthcare excellence.
Asro
Basiran
